For the year ending 2025-12-31, CRMD had $105,069K increase in cash & cash equivalents over the period. $172,786K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 163,055 |
| Stock-based compensation | 13,832 |
| Change in right-of-use assets | 438 |
| Depreciation | 677 |
| Amortization of intangible | 13,872 |
| Change in contingent consideration | -6,501 |
| Change in fair value of equity securities | -5,364 |
| Deferred income taxes | -25,797 |
| Amortization of debt finance costs | 398 |
| Provision for current expected credit losses | -252 |
| Gain on liquidation of foreign entity | 86 |
| Increase in account receivables | 90,924 |
| Increase in inventory | 3,478 |
| Increase in prepaid expenses and other current assets | 2,061 |
| (decrease) increase in accounts payable | 3,329 |
| Increase in accrued expenses | 100,771 |
| Decrease in operating lease liabilities | -308 |
| Payment of contingent liability | 61 |
| Net cash provided by (used in) operating activities | 175,046 |
| Acquisitions of businesses, net of cash acquired | 308,511 |
| Investment in equity securities | 5,000 |
| Purchase of short-term investments | 47,952 |
| Maturity of short-term investments | 55,293 |
| Purchase of equipment | 2,260 |
| Net cash provided by (used in) investing activities | -308,430 |
| Proceeds from sale of common stock from public offering, net | 82,370 |
| Proceeds from senior convertible notes | 150,000 |
| Proceeds from sale of common stock from at-the-market program, net | 7,788 |
| Payment of employee withholding taxes on vested restricted stock units | 1,988 |
| Proceeds from exercise of stock options | 6,389 |
| Payment of debt issuance costs associated with the convertible notes | 5,729 |
| Payment of contingent consideration liabilities | 189 |
| Rou financing lease fees | 188 |
| Net cash provided by financing activities | 238,453 |
| Net (decrease) increase in cash and cash equivalents | 105,069 |
| Cash and cash equivalents and restricted cash beginning of year | 40,756 |
| Cash and cash equivalents and restricted cash end of year | 145,825 |
CorMedix Inc. (CRMD)
CorMedix Inc. (CRMD)